Genetic polymorphisms of metabolizing enzymes and transporters correlate with pharmacokinetics (PK) and pharmacodynamics (PD) of amrubicin

Genetic polymorphisms of metabolizing enzymes and transporters correlate with pharmacokinetics (PK) and pharmacodynamics (PD) of amrubicin - PK/PD and PGx study of Amrubicin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002970

Enrollment

Registered

2010-01-04

Start date

2008-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

patients is recieved amrubicin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: lung cancer Informed consent is given

Exclusion criteria

Exclusion criteria: possitive HIV and HCV, and Hbs Patients whose participation inthe trial is judged to be inappropriate by the attending doctor

Design outcomes

Primary

Measure	Time frame
PK parameter of amrubicin and active metabolite amrubicinol	—

Secondary

Measure	Time frame
PK parameters correlate with Hematological toxicity Genetic polymorphisms correlate with PK/PD	—

Countries

Japan

Contacts

Public ContactYoshinori Makino

National Cancer Center Hospital Department of Pharmacy

ymakino@ncc.go.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026